SCHEMBL6490457

SCHEMBL6490457

CCOP(=O)(O)CC(=O)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.59
NR4A2 P43354 5/20 0.58
PTPN1 P18031 1/20 0.57
SMPD1 P17405 2/20 0.56
SRD5A2 P31213 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
NR1H4 Q96RI1 1/20 0.50
CYP19A1 P11511 1/20 0.49
FAAH O00519 1/20 0.49
CNR2 P34972 1/20 0.49
GPR132 Q9UNW8 1/20 0.49
GUSB P08236 1/20 0.48
NR4A1 P22736 1/20 0.47
NR4A3 Q92570 1/20 0.47
TP53 P04637 1/20 0.47
PKM P14618 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5732744 0.93 MRGPRX4 (0.56) MAOBNR4A2PTPN1SMPD1TP53
SCHEMBL5734501 0.88 KMT2A (0.46) MAOBNR4A2PTPN1SMPD1MEN1
SCHEMBL5733422 0.87 RAB9A (0.51) MEN1KMT2ANR1H4TP53SMN1; SMN2
SCHEMBL5733094 0.85 ERCC5 (0.53) MEN1KMT2APKMSMN1; SMN2
SCHEMBL6485002 0.84 NR4A2 (0.60) MAOBNR4A2PTPN1MEN1KMT2A
SCHEMBL5734272 0.83 SMPD1 (0.53) SMPD1MEN1KMT2ANR1H4TP53
SCHEMBL5734543 0.83 LMNA (0.42) PTPN1TP53PKMNFKB1NFKB2
SCHEMBL5732673 0.82 CES2 (0.51) MEN1KMT2ASMN1; SMN2
SCHEMBL6490447 0.81 MAOB (0.63) MAOBNR4A2PTPN1SMPD1SRD5A2
SCHEMBL5734228 0.81 CYP4F2 (0.42) CNR2TP53PKMNFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 MAOB 2161/4885NR4A2 166/4885PTPN1 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.